There is great hope in implementing ALKi therapy in a neoadjuvant setting and across the board in lung cancers, but particularly given that later-generation ALKi’s are highly potent to ALK, delivering objective response rates of more than 70%–80%, far superior to chemotherapy in the advanced setting. The gene discussed is ALK; the disease is lung carcinoma.